Accès gratuit
Numéro
Réanimation
Volume 24, Numéro 3, Mai 2015
Infectieux
Page(s) 270 - 277
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1059-1
Publié en ligne 1 avril 2015
  • Rottier WC, Amerlaan H, Bonten M (2012) Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67:1311–1320 [CrossRef] [PubMed] [Google Scholar]
  • Oteo J, Perez-Vazquez M, Campos J (2010) Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 23:320–326 [CrossRef] [PubMed] [Google Scholar]
  • Collins VL, Marchaim D, Pogue JM, et al (2012) Efficacy of ertapenem for treatment of bloodstream infections caused by extendedspectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 56:2173–2177 [CrossRef] [PubMed] [Google Scholar]
  • Hombach M, Mouttet B, Bloemberg GV (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of EBSL-and AmpC β-lactamases producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 68:2092–2098 [CrossRef] [PubMed] [Google Scholar]
  • Betriu C, Salso S, Sánchez A, et al (2006) Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 28:1–5 [CrossRef] [PubMed] [Google Scholar]
  • Wu N, Chen B, Tian S, et al (2014) The inoculum effect of antibiotics against CTX-M-extended-spectrum ß-lactamase-producing Escherichia coli. Ann Clin Microbiol Antimicrob 13:45 [PubMed] [Google Scholar]
  • Afssaps (2011) Dix ans d’évolution des consommations d’antibiotiques en France. http://wwwafssapsfr/var/afssaps_site/storage/original/application/263354f238b8f7061cdb52319655ca07 [Google Scholar]
  • Nordmann P, Naas T, Poirel L (2011) Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798 [CrossRef] [PubMed] [Google Scholar]
  • Nordmann P (2014) Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 44:51–56 [CrossRef] [PubMed] [Google Scholar]
  • Brun-Buisson C, Legrand P, Philippon A, et al (1987) Transferable enzymatic resistance to third-genera-tion cephalosporins during nosocomial outbreak of multiresis-tant Klebsiella pneumoniae. Lancet 2:302–306 [CrossRef] [PubMed] [Google Scholar]
  • Sader HS, Hsiung A, Fritsche TR, et al (2007) Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 57:341–344 [CrossRef] [Google Scholar]
  • Labombardi VJ, Rojtman A, Tran K (2006) Use of cefepime for the treatment of infections caused by extended spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 56:313–315 [CrossRef] [Google Scholar]
  • Zanetti G, Bally F, Greub G, et al (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447 [CrossRef] [PubMed] [Google Scholar]
  • Kahlmeter G (2008) Breakpoints for intravenously used cephalosporins in Enterobacteriaceae — EUCAST and CLSI breakpoints. Clin Microbiol Infect 14:S169–S174 [CrossRef] [Google Scholar]
  • Kotapati S, Kuti JL, Nightingale CH, et al (2005) Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 51:211–217 [CrossRef] [PubMed] [Google Scholar]
  • Lee NY, Lee CC, Huang WH, et al (2013) Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum β-lactamase–producing Enterobacteriaceae: MIC Matters. Clin Infect Dis 56:488–495 [CrossRef] [PubMed] [Google Scholar]
  • Andes D, Craig WA (2005) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11:10–17 [CrossRef] [PubMed] [Google Scholar]
  • Martínez J, Cobos-Trigueros A, Soriano A, et al (2010) Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 54:3590–3596 [CrossRef] [PubMed] [Google Scholar]
  • Paterson DL, Ko WC, Von Gottberg A, et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212 [CrossRef] [PubMed] [Google Scholar]
  • Kang CI, Kim SH, Park WB, et al (2004) Bloodstream infections due to extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581 [CrossRef] [PubMed] [Google Scholar]
  • Falagas ME, Tansarli GS, Rafailidis PI (2012) Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother 56:4214–4222 [CrossRef] [PubMed] [Google Scholar]
  • Goethaert K, Van Looveren M, Lammens C, et al (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12:56–62 [CrossRef] [PubMed] [Google Scholar]
  • Ambrose PG, Bhavnani SM, Jones RN (2003) Pharmacokinetics pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 47:1643–1646 [CrossRef] [PubMed] [Google Scholar]
  • Canoui E, Tankovic J, Bige N, et al (2014) Which proportion of extended-spectrum β-lactamase producing strains could be treated by non-carbapenem beta-lactams? Med Mal Inf 44:232–237 [CrossRef] [Google Scholar]
  • Comité de l’antibiogramme de la Société française de microbiologie. Argumentaire pour les recommandations faites en 2011 à propos des C3G et de l’aztréonam vis-à-vis des entérobactéries. http://www.infectiologie.com/site/medias/Recos/2011-Argu-Reco-CaSFM.pdf [Google Scholar]
  • Rodriguez-Bano J, Navarro M, Retamar P, et al (2012) β-Lactam/ β-Lactam inhibitor combinations for the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli: a post-hoc analysis of prospective cohorts. Clin Infect Dis 54:167–174 [CrossRef] [PubMed] [Google Scholar]
  • Retamar P, Lopez-Cerero L, Muniain MA, et al (2013) Impact of the MIC of piperacillin/tazobactam on the outcome of patients with bacteriema due to extended spectrum beta lactamase producing Escherichia coli. Antimicrob Agents Chemother 57:3402–3404 [CrossRef] [PubMed] [Google Scholar]
  • Pal RB, Pal P, Jain S, et al (2008) In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime + clavulanic acid among β-lactamase positive clinical isolates of gram-positive and Gram-negative pathogens. J Indian Med Assoc 106:545–548 [PubMed] [Google Scholar]
  • Vardakas KZ, Tansarli GS, Rafailidis PI, et al (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67:2793–2803 [CrossRef] [PubMed] [Google Scholar]
  • Gauzit R, Craig A, Brun-Buisson C, et al (2010) Recommandations de bon usage des carbapénèmes. J Anti Inf 12:183–189 [Google Scholar]
  • Emery CL, Weymouth LA (1997) Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 35:2061–2067 [PubMed] [Google Scholar]
  • Ho PL, Chan WM, Tsang KW, et al (2002) Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 34:567–573 [CrossRef] [PubMed] [Google Scholar]
  • Suankratay C, Jutivorakool K, Jirajariyavej S (2008) A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum β-lactamase-producing bacteria. J Med Assoc Thai 91:1172–1181 [PubMed] [Google Scholar]
  • Asakura T, Ikeda M, Nakamura A, et al (2014) Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Infect Dis 29:91–95 [CrossRef] [PubMed] [Google Scholar]
  • Lepeule R, Ruppe E, Le P, Massias L, et al (2012) Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother 56:1376–1381 [CrossRef] [PubMed] [Google Scholar]
  • Bin C, Hui W, Renyuan Z, et al (2006) Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56:351–357 [CrossRef] [Google Scholar]
  • Dudley MN, Ambrose PG, Bhavnani SM, et al (2013) Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: cephalosporins and aztreonam. Clin Infect Dis 56:1301–1309 [CrossRef] [PubMed] [Google Scholar]
  • Karim A, Poirel L, Nagarajan S, et al (2001) Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 201:237–241 [PubMed] [Google Scholar]
  • Jacoby GA, Carreras I (1990) Activities of βlactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 34:858–862 [CrossRef] [PubMed] [Google Scholar]
  • Pangon B, Bizet C, Bure A, et al (1989) In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 159:1005–1006 [CrossRef] [PubMed] [Google Scholar]
  • Balakrishnan I, Awad-El-Kariem FM, Aali A, et al (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66:2628–2631 [CrossRef] [PubMed] [Google Scholar]
  • Zhanel GG, Lawson CD, Adam H, et al (2013) Ceftazidime–avibactam: a novel cepha-losporin/βlactamase inhibitor combination. Drugs 73:159–177 [CrossRef] [PubMed] [Google Scholar]
  • Flamm R, Sader H, Farrell D, et al (2014) Ceftazidime–avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80:233–238 [CrossRef] [Google Scholar]
  • Bhalodi AA, Crandon JL, Williams G, et al (2014) Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in at high model. Int J Antimicrob Agents 44:508–513 [CrossRef] [PubMed] [Google Scholar]
  • Yoshizumi A, Ishii Y, Aoki K, et al (2015) In vitro susceptibility of characterized β-lactamase-producing Gram negative bacteria solated in Japan to ceftazidime, ceftaroline, and aztreonam–avibactam combinations, J Infect Chemother 21:148–51 [CrossRef] [Google Scholar]
  • Walkty A, Adam H, Baxter M, et al (2014) In vitro activity of plazomicin against 5015 Gram-negative and Gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother 58:2554–2563 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, Righi E (2014) Eravacycline for the treatment of intraabdominal infections. Expert Opin Investig Drugs 23:1575–1584 [CrossRef] [PubMed] [Google Scholar]
  • Mensa B, Howell GL, Scott R, et al (2014) Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58:5136–5145 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.